Business
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgi
About this update from Treace Medical Concepts, Inc.
[{"type":"image","alt":"Treace Medical Concepts, Inc.","displaySize":"","headline":null,"caption":"Treace Medical Concepts, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vLorRmISLl3PfaqwwnfXfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363","width":300,"height":60}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology.","length":364,"tagName":"p"},{"type":"text","content":"Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, precisely correct in all three planes, and further streamline procedural workflow with Treace’s SpeedPlate® Rapid Compression Fixation technology.","length":292,"tagName":"p"},{"type":"text","content":"“As the pioneers and leaders in instrumented 3D bunion correction, Lightning technology demonstrates our commitment to continuous advancement of our patented Lapiplasty® System, improving surgical efficiency and precision and expanding its appeal to more surgeons,” said John T. Treace, CEO and Chairman of Treace. “We anticipate initiating our limited market release of the Lapiplasty® Lightning™ System midyear 2026 in advance of full commercialization, which we expect before the end of year.”","length":496,"tagName":"p"},{"type":"text","content":"William T. DeCarbo, DPM, of Greater Pittsburgh Foot & Ankle Center and a member of Treace’s Surgeon Advisory Board, performed the first case with the new Lightning technology and commented, “Lightning integrates years of clinical insights and feedback. I found the instrumentation highly intuitive, allowing me to perform a faster Lapiplasty® Procedure while also providing greater accuracy and control of the 3-plane correction. Having the instrumentation hold the correction from the start of the...